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Context.-A histologic classification of lung cancer subtypes is essential in guiding therapeutic management.
Objective.-To complement morphology-based classification of lung tumors, a previously developed lung subtyping panel (LSP) of 57 genes was tested using multiple public fresh-frozen gene-expression data sets and a prospectively collected set of formalin-fixed, paraffinembedded lung tumor samples.
Design.-The LSP gene-expression signature was evaluated in multiple lung cancer gene-expression data sets totaling 2177 patients collected from 4 platforms: Illumina RNAseq (San Diego, California), Agilent (Santa Clara, California) and Affymetrix (Santa Clara) microarrays, and quantitative reverse transcription-polymerase chain reaction. Gene centroids were calculated for each of 3 genomic-defined subtypes: adenocarcinoma, squamous cell carcinoma, and neuroendocrine; the latter of which encompassed both small cell carcinoma and carcinoid. Classification by LSP into 3 subtypes was evaluated in both fresh-frozen and formalin-fixed, paraffin-embedded tumor samples, and agreement with the original morphologybased diagnosis was determined.
Results.-The LSP-based classifications demonstrated overall agreement with the original clinical diagnosis ranging from 78% (251 of 322) to 91% (492 of 538 and 869 of 951) in the fresh-frozen public data sets and 84% (65 of 77) in the formalin-fixed, paraffin-embedded data set. The LSP performance was independent of tissuepreservation method and gene-expression platform. Secondary, blinded pathology review of formalin-fixed, paraffin-embedded samples demonstrated concordance of 82% (63 of 77) with the original morphology diagnosis.
Conclusions.-The LSP gene-expression signature is a reproducible and objective method for classifying lung tumors and demonstrates good concordance with morphology-based classification across multiple data sets. The LSP panel can supplement morphologic assessment of lung cancers, particularly when classification by standard methods is challenging.
(Arch Pathol Lab Med. doi: 10.5858/arpa.2015-0113-OA) L ung cancer is the leading cause of cancer death in the United States, and more than 220 000 new lung cancer cases are identified each year. 1 It is a heterogeneous disease with subtypes determined by genetics and morphology (ie, small cell carcinoma, carcinoid, adenocarcinoma [ACA] , and squamous cell carcinoma [SQC] ). Classification of morphologic subtypes of lung cancer is essential in guiding optimal patient management, 2 and complementary molecular testing is used to identify mutated oncogene therapeutic targets. Variability in morphology and the need for assessment of a growing list of therapeutically targeted markers pose challenges to the current diagnostic standard because tissue amounts and quality are often limiting features.
Although new therapies are increasingly directed toward specific subtypes of lung cancer (eg, bevacizumab 3 and pemetrexed 4 ), studies of histologic diagnosis reproducibility have shown limited intrapathologist agreement 5 and even less interpathologist agreement. 6, 7 The introduction of the immunohistochemistry (IHC) markers thyroid transcription factor and cytokeratin 7 for ACA, and p63/p40 plus cytokeratin 5/6 for SQC are expected to improve the classification of non-small cell lung cancer, thereby reducing the number of samples that would otherwise be reported as non-small cell lung cancer, not otherwise specified. [8] [9] [10] Nevertheless, poorly differentiated tumors, conflicting IHC results, and small-volume biopsies, in which only a limited number of IHC stains can be performed, continue to pose challenges to the current diagnostic standard. [11] [12] [13] Simultaneously, new genomic data are providing molecular features that enhance the classification of lung tumors beyond what was feasible by morphology alone.
14-16 Therapeutic molecular targets, such as EGFR mutations, ALK rearrangements, ROS1 fusions in ACA, and FGFR1 amplification in SQC, have been found to be histologic subtype specific, thereby emphasizing the need for accurate subtype classification. 15, 16 Further classification within the ACA and SQC subtypes is also being investigated to provide a greater understanding of tumor biology and associated clinical implications. [17] [18] [19] [20] The lung subtype panel (LSP), a 57-gene messenger RNA (mRNA) expression signature (52 classification genes plus 5 housekeeping genes), was developed to address the need for a more-objective means of classifying tumors into the known biologic/histologic subtypes. This method can thus be used to assist the pathologist in classifying lung tumors. 21 In this study, the ability of the LSP gene signature to reliably subtype lung tumor samples using gene expression data from any one of multiple platforms, including Affymetrix (Santa Clara, California) and Agilent (Santa Clara, California) DNA microarrays, RNA sequencing, and quantitative reverse transcription-polymerase chain reaction (qRT-PCR), was investigated. The 57-gene signature was also evaluated in both fresh-frozen (FF) and a new set of formalin-fixed, paraffin-embedded (FFPE) lung tumor samples comprising multiple subtypes of lung tumors, including ACA, SQC, and neuroendocrine (NE) (comprising small cell and carcinoid tumors). Concordance of gene expression-based tumor-subtype classification with the original morphologic diagnosis was evaluated.
METHODS
Multiple data sets, comprising 2177 samples, were assembled to evaluate a previously published 57-gene LSP gene-expression classifier. 21 The ), as well as newly collected geneexpression data from 78 FFPE samples. 27 Data sources are provided in Table 1 , including normalization methods applied to each data set. [28] [29] [30] The 78 FFPE samples were archived residual lung tumor samples, primarily surgical resections, collected at the University of North Carolina, Chapel Hill, under an institutional review boardapproved protocol. Only samples with sufficient residual tissue and a definitive diagnosis of ACA, carcinoid, small cell carcinoma, or SQC were used in the analysis. A total of 4 categories of genomic data were available for analysis: Affymetrix U133þ2 (n ¼ 693), Agilent 44K (n ¼ 344), Illumina RNAseq (San Diego, California) (n ¼ 1062), and newly collected qRT-PCR (n ¼ 78) data.
FFPE Sample Expression Analysis
Archived FFPE lung tumor samples (n ¼ 78) were analyzed using a qRT-PCR gene expression assay as previously described, 21 with the following modifications. RNA was extracted from one 10-lm section of FFPE tissue using the High Pure RNA Paraffin Kit (Roche Applied Science, Indianapolis, Indiana). Extracted RNA was diluted to 5 ng/lL, and first-strand cDNA was synthesized using genespecific 3 0 primers in combination with random hexamers (Superscript III, Invitrogen, Thermo Fisher Scientific, Waltham, Massachusetts). An ABI 7900 (Applied Biosystems, Thermo Fisher Scientific) was used for qRT-PCR with continuous SYBR green fluorescence (530 nm) monitoring. The ABI 7900 quantitation software generated amplification curves and associated cycle threshold values. Gene expression results for these 78 FFPE samples (changes in cycle threshold after imputing, 52 genes) can be found in Supplemental Table 1 (the supplemental digital content contains 5 tables), and original clinical diagnoses gathered with the samples are in Supplemental Table 2 .
Pathology Review
Pathology review was only possible for the FFPE lung tumor cohort in which additional sections were collected and imaged. One section from each of 2 blocks from the same case was stained with hematoxylin-eosin and were scanned using an Aperio ScanScope slide scanner (Aperio Technologies, Vista, California). Virtual slides were viewable at magnifications equivalent to 332 to 3320 objectives (3340 magnifier). Pathologist review (blocks 1 and 2) was blinded to the original clinical diagnosis, to the link of the blocks to a single case, and to the gene expression-based subtype classification. Pathology review-based, histologic-subtype calls were compared with the original clinical diagnosis (n ¼ 78). Agreement for pathology reviews was defined as those samples for which slides from both blocks were assigned the same subtype as the original diagnosis. The IHC staining, including TTF-1, p63, synaptophysin, and/or Ki-67, were available for postgenomic assay testing to help resolve disagreements among the pathology review, gene expression, and original clinical diagnosis.
Data Analysis
All statistical analyses were conducted using R software (version 3.0.2; http://cran.R-project.org, accessed October 15, 2013). Data analyses were conducted separately for FF and FFPE tumor samples.
FF Data Set Analysis.-Data sets were normalized, as described in Table 1 . The Affymetrix data set served as the training set for calculation of ACA, carcinoid, small cell carcinoma, and SQC gene centroids, according to methods described previously. 20, 21 Affymetrix training-gene centroids are provided in Supplemental Table 3 . The training-set gene centroids were tested in normalized TCGA RNAseq gene expression and Agilent microarray gene-expression data sets. Because of missing data from the public Agilent data set, the Agilent evaluations were performed with a 47-gene classifier, rather than a 52-gene panel with exclusion of the following genes: CIB1, FOXH1, LIPE, NCAM1 (PCAM1), and TUBA4A (TUBA1).
Evaluation of the Affymetrix data was performed using Leave One Out (LOO) cross-validation. Spearman correlations were calculated for tumor test sample to the Affymetrix gene-expression training centroids. Tumors were assigned a genomic-defined histologic type (ACA, SQC, or NE) corresponding to the maximally correlated centroids. Correct predictions were defined as LSP calls matching the tumor's original histologic diagnosis. Percent agreement was defined as the number of correct predictions divided by the number of total predictions and an agreement kappa statistic was calculated.
qRT-PCR From FFPE Sample Analysis.-Previously published training centroids, 21 calculated from qRT-PCR data of FFPE lung tumor samples, were cross-validated in this new sample set of qRT-PCR gene expressions from FFPE lung tumor tissue. The ACA and SQC centroids were used as published. 21 The NE gene centroids were calculated similarly using published gene-expression data (n ¼ 130). 21 The Wilkerson et al 21 gene centroids for the FFPE tissue evaluation are included in Supplemental Table 4 . The FFPE sample gene-expression data were scaled to align gene variance with Wilkerson et al 21 data. A gene-specific scaling factor was calculated that accounted for label-frequency differences between the data sets. Gene expression data were then median-centered, signflipped (high threshold cycle ¼ low abundance), and scaled using RESULTS Ten lung tumor gene-expression data sets, including 9 FF data sets plus 1 new FFPE qRT-PCR gene-expression data set, were combined into 4 platform-specific data sets (Affymetrix, Agilent, Illumina RNAseq, and qRT-PCR). For the data sets in which clinical information was available, the patient population was diverse and included smokers and nonsmokers with tumors ranging from stage 1 to stage IV. Sample characteristics and lung cancer diagnoses from the data sets used in this study are included in Table 2 . After exclusion of samples without a definitive diagnosis of ACA, SQC, small cell carcinoma, or carcinoid, and exclusion of 1 FFPE sample that failed qRT-PCR analysis, the following samples were available for further data analysis: Affymetrix (n ¼ 538), Agilent (n ¼ 322), Illumina RNAseq (n ¼ 951), and qRT-PCR (n ¼ 77). Samples excluded from analysis included non-small cell lung cancer, not otherwise specified; carcinoma, not otherwise specified; large cell carcinoma; large cell NE carcinoma adenosquamous carcinoma, and normal tissue.
As a means of de novo evaluation of the new FFPE data set, we performed hierarchic clustering of LSP gene expression from the FFPE archived samples (n ¼ 77); as expected, this analysis demonstrated 3 clusters/subtypes corresponding to ACA, SQC, and NE (Figure 1) . The predetermined LSP 3-subtype centroid predictor was then applied to all 4 data sets, and results were compared with tumor morphologic classifications. Percentage of agreement and Fleiss j statistics were calculated for each data set ( Table  3 ). The percentage of agreement ranged from 78% (251 of 322) to 91% (492 of 538), with a Fleiss j range of 0.57 to 0.85.
As another means of assessing independent pathology agreement, the agreement of the blinded pathology review of the 77 FFPE lung tumors with the original morphologic diagnosis was found to be 82% (63 of 77). In 12 of 77 cases (16%), blinded slides from the 2 blocks of the same case provided conflicting results, and in 10 of 77 cases (13%), at least 1 of the blocks had a nondefinitive pathologic subtype classification of adenosquamous, large cell carcinoma, or high-grade, poorly differentiated carcinoma. Comparison of the original morphologic diagnosis, blinded pathology review, and gene-expression LSP subtype determinations for each of the 77 samples is shown in Figure 2 .
For the 20 cases in which any discrepancy from the original clinical diagnosis was identified (Figure 2 ), slides were examined following specific IHC staining (TTF-1, p63, synaptophysin, Ki-67) to help resolve the differences. Residual slides were available for IHC staining in 17 of 20 FFPE cases (85%). The LSP results were confirmed by IHC testing in 11 of 17 cases (65%) and disagreed with IHC in 2 of 17 cases (12%), including 1 ACA and 1 SQC. In 4 of 17 cases (24%), a definitive diagnosis was not possible, despite the use of multiple IHC stains. Full details of IHC testing and discrepancy resolution are provided in Supplemental Table 5 . Agreement of the LSP assay with the original and/ or the revised morphology diagnosis (with incorporation of multiple IHC stains) was at least as good as the concordance between any 2 pathologists, [5] [6] [7] thus suggesting that the LSP assay performed at least as well as a trained pathologist.
COMMENT
The classification of a lung cancer into various histologic subtypes is increasingly important because therapeutic development and patient management have become more-specifically targeted to unique features of each tumor. Emerging data from multiple studies suggest that molecular profiles have the potential to improve the morphologic diagnoses of lung tumors and to better characterize tumors for therapeutic decision making. [14] [15] [16] 19, 20 Several recent studies now suggest that large cell carcinoma and large cell NE tumors represent a mixture of tumor types, which may actually be more similar to ACA, SQC, or small cell lung cancer, when examined by IHC and/or molecular features.
14, 31, 32 The value of accurately defining the tumor histologic subtype, while preserving as much tissue as possible for molecular assays, has clear therapeutic implications, as is evident in practice management guidelines and drug prescribing information in which histologic subtype dictates many of the drugs that a patient is to recieve.
2,13
The LSP gene-expression signature has previously been shown to provide reliable classifications of lung cancer subtype. 21 In this study of many additional data sets, the LSP assay provided reliable subtype classifications, validating its performance across multiple gene-expression platforms, even when using FFPE specimens. Hierarchic clustering of the newly assayed FFPE samples demonstrated good separation among the 3 subtypes (ACA, SQC, and NE) based on expression of 52 genes. Concordance with morphology diagnosis when using the LSP centroids was greatest in the TCGA RNAseq data set (agreement, 91%; 869 of 951), possibly because of the extensive pathology review and accuracy of the histologic diagnosis associated with TCGA samples as compared with other data sets. Agreement was lowest (78%; 251 of 322) in the Agilent data set, which may have been affected by the reduced number of genes that were available for that analysis. Overall, the LSP assay displayed a higher concordance with the original morphology diagnosis than the pathology review in all data sets, except in the Agilent data set, in which only 47 genes, rather than 52, were present for the analysis.
In the FFPE samples, for which blinded pathology review was possible, results suggest that pathology calls were not always consistent in duplicate blocks from the same case nor were they necessarily consistent with the original diagnosis. In this study, IHC testing improved the pathology review concordance with the original clinical diagnosis from 63 of 77 (82%) to 66 of 77 (86%); however, 4 samples could still not be resolved, despite the use of multiple IHC stains, and 3 samples could not be resolved because of insufficient tissue material for IHC testing. The IHC testing, although helpful in some cases, was not able to universally resolve ACA versus SQC cases. Studies have shown that 30% of ACA samples may be immunoreactive to p63 and 10% of ACA may not be immunoreactive to TTF-1. 8 These findings highlight the challenges of lung cancer classification and are consistent with several other publications documenting the variability in lung tumor histologic morphology-based diagnoses, [5] [6] [7] 33 as well as the limits of IHC staining. ACA  419  21  28  468  131  6  37 174  248  0  16  264  13  2  6  21  NE  NA  NA  NA  NA  NA NA NA  NA  2  43  2  47  1  29  1  31  SQC  22  11  450  483  27  1 120 148  26  0  201  227  1  1  23  25  Sum  441  32  478  951  158  7 157 322  276  43  219  538  15  32  30 This study was limited by a number of features, including a low number of NE tumor samples in the Affymetrix data set and the absence of NE samples in both the Agilent and TCGA data sets. This limitation was partially overcome by a relatively high number of NE samples in the FFPE sample set (31 of 77; 40%), thus providing a good test of the ability of the LSP gene signature to identify NE samples. Another limitation of the study relates to the blinded pathology rereview. The blinded pathology review was based on single-imaged sections from 2 separate blocks of a single case and did not reflect the usual histology standard practice in which multiple sections or blocks and potentially multiple IHC stains would have been available to make a single diagnosis. The addition of IHC testing to resolve the discrepancies was helpful in addressing the deficiency in this study, but it also demonstrated some the limits of IHC testing in this setting. Final results suggest that our level of pathology agreement was very similar to several past studies [5] [6] [7] and was only marginally improved with IHC testing. A recent example involving expert pathology rereview of lung cancer samples submitted to the TCGA Lung Cancer Genome Project led to the reclassification of 16% to 20% (SQC, 35 of 213; ACA, 59 of 289 ACA) of lung tumors submitted, 15, 16 confirming similar levels of disagreement and the ongoing challenge of morphology-based diagnoses.
Expanded use of molecular testing in characterizing lung tumors is inevitable, and we feel, is desirable because genomics drives biologically based classifications, which lead to improved therapeutics and more-personalized oncology treatment plans. Despite the limitations of this study, molecular profiling using the LSP assay was validated in more than 2000 samples from multiple data sets, from multiple institutions, and from multiple technology platforms. Molecular profiling compared favorably to lightmicroscopy-derived diagnoses and showed at least as high a level of agreement with the original diagnosis as did the pathologist reassessments. Gene expression-based tumor subtyping can provide valuable information in the clinic and may be especially helpful when tissue is limited, IHC results are inconclusive, and/or when the morphologic diagnosis remains unclear. This study was primarily restricted to samples from surgical resections in which sufficient residual tissue and a definitive diagnosis was available for analysis. Ongoing initiatives are now specifically focusing on the more difficult task of classifying samples, including smallvolume biopsies and/or cytology samples. Independent of the tissue preservation or the gene expression method used, the LSP panel of biologically relevant genes provided a reliable adjunct to standard histopathology.
